Market closed
Bristol-Myers Squibb/$BMY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
34,100
Website
BMY Metrics
BasicAdvanced
$121B
-
-$3.58
0.44
$2.40
4.16%
Price and volume
Market cap
$121B
Beta
0.44
52-week high
$60.00
52-week low
$39.35
Average daily volume
11M
Dividend rate
$2.40
Financial strength
Current ratio
1.24
Quick ratio
1.016
Long term debt to equity
291.826
Total debt to equity
299.052
Interest coverage (TTM)
5.05%
Management effectiveness
Return on assets (TTM)
6.07%
Return on equity (TTM)
-31.33%
Valuation
Price to revenue (TTM)
2.549
Price to book
7.06
Price to tangible book (TTM)
-3.83
Price to free cash flow (TTM)
8.759
Dividend yield (TTM)
4.02%
Forward dividend yield
4.16%
Growth
Revenue change (TTM)
5.56%
Earnings per share change (TTM)
-190.85%
3-year revenue growth (CAGR)
1.42%
3-year earnings per share growth (CAGR)
13.96%
3-year dividend per share growth (CAGR)
6.98%
What the Analysts think about BMY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
BMY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BMY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BMY News
AllArticlesVideos
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
Business Wire·2 days ago
Final Trade: ET, DELL, KRE, BMY
CNBC Television·3 days ago
Top 4 Immunology Stocks Poised For Growth In 2025
Seeking Alpha·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Feb3
Bristol-Myers Squibb
Dividend·Payment
$0.62
Per share
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $121B as of January 27, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 0 as of January 27, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of January 27, 2025, the dividend rate is $2.4 and the yield is 4.16%. Bristol-Myers Squibb has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for February 03, 2025.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.